Keyphrases
Phase II Study
80%
Phase II Trial
77%
Soft Tissue Sarcoma
72%
Sarcoma
68%
Ripretinib
62%
Regorafenib
49%
Progression-free Survival
49%
Advanced Gastrointestinal Stromal Tumor
47%
Placebo
45%
Tumor
38%
Leiomyosarcoma
38%
Overall Survival
37%
Metastatic Soft Tissue Sarcoma
37%
Pazopanib
36%
INVICTUS
35%
Angiosarcoma
35%
Desmoid Tumor
35%
Confidence Interval
35%
Dedifferentiated Liposarcoma (DDLPS)
34%
Median Progression-free Survival
31%
Bone Sarcoma
29%
Synovial Sarcoma
29%
Chordoma
28%
Pembrolizumab
28%
Imatinib
28%
Sunitinib
27%
Gemcitabine
26%
Docetaxel
26%
Clinical Activity
24%
Adverse Events
23%
Ewing Sarcoma
23%
Patient-reported Outcomes
22%
Partial Response
21%
Gastrointestinal Stromal Tumor
20%
Median Overall Survival
20%
Advanced Soft Tissue Sarcoma
20%
Objective Response Rate
20%
Non-resectable
20%
Chemotherapy
19%
Clinical Benefit
19%
Radiation Therapy
19%
Treatment Refractory
19%
Doxorubicin
18%
Myxoid
18%
Randomized Placebo-controlled Trial
18%
Liposarcoma
18%
Resection
18%
Programmed Death-ligand 1 (PD-L1)
17%
Evofosfamide
17%
Selinexor
17%
Pharmacology, Toxicology and Pharmaceutical Science
Progression Free Survival
78%
Soft Tissue Sarcoma
75%
Ripretinib
62%
Gastrointestinal Stromal Tumor
62%
Placebo
59%
Overall Survival
47%
Regorafenib
45%
Neoplasm
36%
Gemcitabine
35%
Adverse Event
31%
Imatinib
29%
Clinical Trial
28%
Connective Tissue Cancer
27%
Pazopanib
27%
Sunitinib
27%
Docetaxel
26%
Desmoid Tumor
26%
Chemotherapy
24%
Diseases
22%
Prostate Cancer
22%
Leiomyosarcoma
22%
Liposarcoma
21%
Malignant Neoplasm
20%
Phase II Trials
20%
Dedifferentiated Liposarcoma
17%
Olaratumab
17%
Evofosfamide
17%
Osteosarcoma
17%
Angiosarcoma
17%
Selinexor
17%
Dacarbazine
17%
Chordoma
17%
Doxorubicin
17%
Tolerability
15%
Disease Exacerbation
14%
Solid Malignant Neoplasm
14%
Synovial Sarcoma
13%
Ribonucleotide Reductase
11%
Biological Marker
11%
Pharmacokinetics
11%
Ewing Sarcoma
11%
Maximum Tolerated Dose
10%
Carotuximab
8%
Nirogacestat
8%
Metastatic Breast Cancer
8%
Infusion Related Reaction
8%
Sulindac Sulfone
8%
3 Aminopicolinaldehyde Thiosemicarbazone
8%
Capecitabine
8%
Randomized Clinical Trial
8%
Medicine and Dentistry
Soft Tissue Sarcoma
100%
Connective Tissue Cancer
86%
Neoplasm
70%
Progression Free Survival
45%
Arm
44%
Diseases
42%
Leiomyosarcoma
37%
Angiosarcoma
35%
Desmoid Tumor
35%
Overall Survival
35%
Synovial Sarcoma
31%
Regorafenib
29%
Adverse Event
29%
Pembrolizumab
28%
Pazopanib
26%
Malignant Neoplasm
24%
Gastrointestinal Stromal Tumor
23%
Ewing Sarcoma
23%
Cancer
21%
Chordoma
20%
Placebo
19%
Ripretinib
17%
Gemcitabine
17%
Liposarcoma Cell
17%
Retroperitoneal Sarcoma
17%
Randomized Clinical Trial
17%
Radiation Therapy
17%
Cancer Treatment
16%
Osteosarcoma
16%
Oncology
15%
Clinical Trial
15%
Targeted Therapy
14%
Dedifferentiated Liposarcoma
13%
Esophagus
13%
Doxorubicin
13%
Disease Free Survival
12%
Prostate Cancer
11%
Endoscopic Ultrasound
11%
Immunotherapy
11%
Intention-to-Treat Analysis
11%
Liposarcoma
10%
Neutropenia
10%
Prognostic Factor
10%
Metastatic Carcinoma
10%
Vasculotropin
10%
Imatinib
9%
Carcinogenesis
9%
Triamcinolone
8%
Triamcinolone Acetonide
8%
Perineum
8%